Royal Bank of Canada’s Putnam BioRevolution ETF SYNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-13,024
| Closed | -$389K | – | 7622 |
|
|
2025
Q3 | $389K | Buy |
13,024
+11,508
| +759% | +$341K | ﹤0.01% | 4663 |
|
|
2025
Q2 | $43K | Sell |
1,516
-592
| -28% | -$16.2K | ﹤0.01% | 5991 |
|
|
2025
Q1 | $59K | Sell |
2,108
-2,410
| -53% | -$71.4K | ﹤0.01% | 5509 |
|
|
2024
Q4 | $134K | Sell |
4,518
-390
| -8% | -$12.2K | ﹤0.01% | 5143 |
|
|
2024
Q3 | $162K | Buy |
4,908
+3,919
| +396% | +$125K | ﹤0.01% | 4989 |
|
|
2024
Q2 | $31K | Sell |
989
-329
| -25% | -$10.1K | ﹤0.01% | 5879 |
|
|
2024
Q1 | $41K | Sell |
1,318
-19,639
| -94% | -$585K | ﹤0.01% | 5628 |
|
|
2023
Q4 | $610K | Buy |
20,957
+20,841
| +17,966% | +$558K | ﹤0.01% | 4095 |
|
|
2023
Q3 | $3K | Sell |
116
-7,064
| -98% | -$197K | ﹤0.01% | 6734 |
|
|
2023
Q2 | $199K | Sell |
7,180
-7,885
| -52% | -$216K | ﹤0.01% | 4757 |
|
|
2023
Q1 | $411K | Sell |
15,065
-2,793
| -16% | -$74.7K | ﹤0.01% | 4035 |
|
|
2022
Q4 | $464K | Buy |
+17,858
| New | +$463K | ﹤0.01% | 4178 |
|
Royal Bank of Canada's SYNB Position: Q4 2025 in Review
Royal Bank of Canada sold out of Putnam BioRevolution ETF (SYNB) in Q4 2025, closing a stake of 13,024 shares — an estimated $389K sold.
Royal Bank of Canada first reported a position in SYNB in Q4 2022 and held it in 12 quarters. The position peaked at $610K in Q4 2023. 0 funds tracked by Wall St. Rank hold SYNB as of Q4 2025.
- Royal Bank of Canada reported no remaining Putnam BioRevolution ETF position as of Q4 2025 after selling out during the quarter.
- Royal Bank of Canada sold 13,024 Putnam BioRevolution ETF shares in Q4 2025, an estimated $389K.
- Royal Bank of Canada first reported a position in Putnam BioRevolution ETF in Q4 2022 and held it in 12 quarters.
- Royal Bank of Canada's Putnam BioRevolution ETF position peaked at $610K in Q4 2023.
- 0 funds tracked by Wall St. Rank held Putnam BioRevolution ETF as of Q4 2025.
Based on Royal Bank of Canada's 13F filing for Q4 2025, filed 17 Feb 2026.